In last trading session, Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) saw 0.71 million shares changing hands with its beta currently measuring 2.30. Company’s recent per share price level of $68.11 trading at $1.93 or 2.92% at ring of the bell on the day assigns it a market valuation of $4.33B. That closing price of RYTM’s stock is at a discount of -0.69% from its 52-week high price of $68.58 and is indicating a premium of 42.96% from its 52-week low price of $38.85.

For Rhythm Pharmaceuticals Inc (RYTM), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.62 in the current quarter.

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) trade information

Rhythm Pharmaceuticals Inc’s shares saw a change of 21.67% in year-to-date performance and have moved 11.05% in past 5-day. Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) showed a performance of 5.38% in past 30-days.

Wall Street analysts have assigned a consensus price target of 78 to the stock, which implies a rise of 12.68% to its current value. Analysts have been projecting 70 as a low price target for the stock while placing it at a high target of 80. It follows that stock’s current price would drop -2.77% in reaching the projected high whereas dropping to the targeted low would mean a loss of -2.77% for stock’s current value.

Rhythm Pharmaceuticals Inc (RYTM) estimates and forecasts

This year revenue growth is estimated to rise 34.86% from the last financial year’s standing.

11 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 43.72M for the same. And 11 analysts are in estimates of company making revenue of 46.92M in the next quarter. Company posted 29.08M and 33.25M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -2.34% during past 5 years.

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM)’s Major holders

PRIMECAP MANAGEMENT CO/CA/ is the top institutional holder at RYTM for having 7.31 million shares of worth $300.25 million. And as of 2024-06-30, it was holding 11.9852 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 6.74 million shares on 2024-06-30. The number of shares represents firm’s hold over 11.0502 of outstanding shares, having a total worth of $276.82 million.

On the other hand, PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 3.87 shares of worth $263.64 million or 6.08% of the total outstanding shares. The later fund manager was in possession of 1.94 shares on Mar 31, 2025 , making its stake of worth around $131.82 million in the company or a holder of 3.04% of company’s stock.